Emerging Treatments in SCLC: Triplets + Limited-Stage Disease
August 19th 2021Anne Chiang, MD, PhD, reviews the study design of 2 clinical trials, adding a third agent to the standard-of-care regimen of chemotherapy plus I/O; Stephen Liu, MD, discusses clinical trials in limited-stage disease.
Read More
Treatment Considerations: Chemotherapy + IO in ES SCLC
July 22nd 2021Panelists reflect on key points from recent studies in ES SCLC by discussing patients for whom immunotherapy may be appropriate, examining the role of adding CTLA4 inhibition to a PD-L1 inhibitor, and reviewing factors to consider when deciding between cisplatin or carboplatin.
Read More
First-Line Therapy in ES SCLS: KEYNOTE-604
July 22nd 2021Key opinion leader in lung cancer, Vivek Subbiah, MD, examines the phase 3 KEYNOTE-604 trial of platinum-based chemotherapy + pembrolizumab and considers whether the data support findings from other trials of chemotherapy + IO combination approaches.
Read More
Dr. Subbiah on the Clinical Activity of Pralsetinib in RET+ Cholangiocarcinoma
January 16th 2021Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.
Read More
Dr. Subbiah on Safety and Efficacy of BLU-667 in RET-Altered Solid Tumors
April 16th 2018Vivek Subbiah, MD, associate medical director, Clinical Center for Targeted Therapy, assistant professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy findings of BLU-667 in RET-altered solid tumors in an interview during the 2018 AACR Annual Meeting.
Read More